AN2 Therapeutics Inc.
Organization details
- Legal name
- AN2 Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Menlo Park
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ANTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001880438
- EIN
- 82-0606654
Board of directors
-
Eric Easom · Director · Chief Executive OfficerSince 2023
-
Gilbert Lynn Marks · DirectorSince 2023
-
Joseph S. Zakrzewski · DirectorSince 2023
-
Kabeer Aziz · DirectorSince 2023
-
Margaret M. FitzPatrick · DirectorSince 2023
-
Melvin K. Spigelman · DirectorSince 2023
-
Patricia A. Martin · DirectorSince 2023
-
Robin Shane Readnour · DirectorSince 2023
-
Stephanie Wong · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
77.4%
-
90.9%
-
91.1%
Board connections
2 of this board's directors also sit on 2 other boards. 2 are in the same sector.
-
Cypherpunk Technologies Inc. Same sectorvia Patricia A. Martin
-
Vistagen Therapeutics Inc. Same sectorvia Margaret M. FitzPatrick
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $11,602
- 1 purchase by 1 insider
- Sold, last 12 months
- $406,105
- 21 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5, 2026 | Eizen Joshua M Officer (See Remarks) | Open-market sale | −2,826 | $4.22 | $11,926 |
| Oct 12, 2026 | Kabeer Aziz Director | Grant or award | +2,465 | — | — |
| Oct 12, 2026 | Patricia A. Martin Director | Grant or award | +389 | — | — |
| Oct 12, 2026 | Gilbert Lynn Marks Director | Grant or award | +2,283 | — | — |
| Sep 15, 2026 | Trenor Cameron C. III Officer (Chief Medical Officer) | Grant or award | +116,667 | — | — |
| Sep 9, 2026 | Robin Shane Readnour Director | Open-market sale | −523 | $6.02 | $3,148 |
| Sep 9, 2026 | Robin Shane Readnour Director | Open-market sale | −585 | $6.02 | $3,522 |
| Sep 8, 2026 | Robin Shane Readnour Director | Open-market sale | −4,725 | $6.02 | $28,445 |
| Sep 8, 2026 | Robin Shane Readnour Director | Open-market sale | −5,294 | $6.02 | $31,870 |
| Sep 3, 2026 | Robin Shane Readnour Director | Open-market sale | −2,877 | $6.07 | $17,463 |
| Sep 3, 2026 | Robin Shane Readnour Director | Open-market sale | −3,223 | $6.07 | $19,564 |
| Sep 1, 2026 | Margaret M. FitzPatrick Director | Open-market purchase | +2,098 | $5.53 | $11,602 |
| Sep 1, 2026 | Williams Sarah Joanne Officer (Principal Accounting Officer) | Open-market sale | −272 | $5.53 | $1,504 |
| Aug 17, 2026 | Robin Shane Readnour Director | Open-market sale | −16,696 | $6.01 | $100,343 |
| Aug 17, 2026 | Robin Shane Readnour Director | Open-market sale | −18,706 | $6.01 | $112,423 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about AN2 Therapeutics Inc.
Who is the CEO of AN2 Therapeutics Inc.?
Eric Easom is AN2 Therapeutics Inc.'s Chief Executive Officer.
How many directors are on AN2 Therapeutics Inc.'s board?
AN2 Therapeutics Inc.'s board has 9 directors: Eric Easom, Gilbert Lynn Marks, Joseph S. Zakrzewski, Kabeer Aziz, Margaret M. FitzPatrick, Melvin K. Spigelman, Patricia A. Martin, Robin Shane Readnour and Stephanie Wong.
Are AN2 Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, AN2 Therapeutics Inc. insiders bought $11,602 of shares in 1 purchase and sold $406,105 of shares in 21 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="an2-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.